TELK's Telintra induces cellular death of leukemia cells while simultaneously promoting new bone marrow and blood cell production. The phase II trial data has shown extended Telintra dosing improves blood cell counts cutting dependence on blood cell transfusions.
Celgene's Revlimid in combination with Telintra is effective and safe in low - risk MDS patients. These findings are published in the Journal of Hematology and Oncology. Celgene's global Revlimid sales total was $2.47 Billion in 2010. The American Cancer Society says over 20,000 new cases of MDS are diagnosed each year.... while GlobalData found there is a high unmet need, implying the market is not served well with current treatment options.
Potential partnering here? You bet Celgene's interested.
Using Due diligence of your own I'm sure you will agree and find TELK undervalued next to peers.
Noticed the past several days on the open and close: "Intermarket sweep orders" Today I did not see it however the up action explains why I have been seeing them. Something is under foot here. I suspect news of a positive nature to be on the horizon.
Due some due diligence here and you will probably see something real is about to happen here.